Aldeyra Therapeutics saw a 12% increase in shares, reaching $3.31, following the announcement of positive topline results from a Phase 2 clinical trial for their atopic dermatitis treatment, ADX-629. Despite a 53% decrease in stock value this year, this recent development brings hope to both the biotechnology company and patients seeking relief from this condition.
During the trial, Aldeyra Therapeutics observed statistically significant and clinically relevant improvements in various physiological and psychosocial assessments. Notably, one patient experienced complete resolution of affected body surface area, while two patients reported the elimination of itching.
Encouraged by the promising activity of ADX-629, Chief Executive Todd Brady expressed enthusiasm in advancing their next-generation investigational RASP modulator, ADX-246. Their plans include initiating Phase 1/2 clinical testing of ADX-246 in the first half of 2024. This multicenter, randomized, placebo-controlled trial will involve healthy volunteers and patients with atopic dermatitis. Topline results are anticipated in the second half of 2024.
These developments mark a significant step forward for Aldeyra Therapeutics in their mission to provide effective treatments for those suffering from atopic dermatitis.
